Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
The New England Journal of Medicine|April 9, 2015
Ibrutinib in previously treated Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Journal of Hematology & Oncology|April 22, 2024
Conventional and novel [<sup>18</sup>F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphomaDoris Leithner, Jessica R Flynn, Sean M Devlin, et al.
Research Square|July 16, 2024
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaJae Park, M Lia Palomba, Karlo Perica, et al.
Transplantation and Cellular Therapy|April 6, 2026
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell LymphomaSilvia Escribano Serrat, Andrew Ip, Jaime Sanz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2025
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell LymphomaJae H Park, M Lia Palomba, Karlo Perica, et al.
Nature Medicine|June 3, 2024
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Saurabh Dahiya, M Lia Palomba, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Pageof 12